Baxter reports FDA subpoena, revises expectations
This article was originally published in Clinica
Executive Summary
Baxter International's haemodialysis nightmare will not go away, with the FDA tightening its investigation of the company's Althane dialysers, and six civil lawsuits over deaths and injuries related to the device pending. Baxter has again revised its sales and earnings expectations for 2003, raising further doubts among the investment community.